Chlamydia trachomatis Detection via pmpA Gene Oligonucleotides

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current diagnostic techniques for Chlamydia trachomatis often yield false-negative results due to strains lacking the cryptic plasmid or variants with a 377 base pair deletion, necessitating more reliable detection methods.

Innovation Solution

The use of oligonucleotides targeting the conserved pmpA gene, specifically amplifying and detecting the region between base pairs 1855 to 2156, to enhance the accuracy of Chlamydia trachomatis detection using SDA or Taqman real-time PCR assays.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If assays target the cryptic plasmid for C. trachomatis detection, then the diagnostic method is widely applicable, but false-negative results occur when strains lack the plasmid or have deletions

Engineering Contradiction:
Improvedetection reliabilityVSAvoidstrain coverage
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the target parameter from the cryptic plasmid to the pmpA gene located on the chromosome. This parameter change ensures detection across all C. trachomatis strains regardless of plasmid presence or variation, resolving the contradiction between detection reliability and strain coverage.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Instead of targeting the optional cryptic plasmid that may or may not be present, the patent inverts the approach by targeting the essential pmpA gene that is universally present in all C. trachomatis strains, thereby eliminating false negatives while maintaining broad applicability.

Inventive Principle:
Principle #13The other way round (Inversion)

2Measurement precision

If assays use highly specific oligonucleotides for accurate detection, then cross-reactivity is minimized, but assay complexity increases

Engineering Contradiction:
Improvedetection accuracyVSAvoidassay complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent applies local quality by designing oligonucleotides that target a specific conserved region within the pmpA gene (base pairs 1855 to 2156). This localized targeting ensures high detection accuracy through species-specific binding while keeping the assay design straightforward and manageable.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a highly reliable and specific method for detecting Chlamydia trachomatis, minimizing cross-reactivity with other organisms or eukaryotic cells, and effectively addressing the limitations of existing assays.

Implementation Method 1

Oligonucleotides described herein may be used to detect the presence of C. trachomatis using the pmpA gene

Methodology Applied
Scientific EffectNucleic acid hybridization:

Implementation Method 2

SDA is an isothermal amplification mechanism and therefore does not involve thermal cycling

Methodology Applied
Scientific EffectStrand displacement amplification:

Data Source

PatentEP2361314B1Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis PMPA gene
Publication Date: 2015.03.18 BECTON DICKINSON & CO
  • EP2361314B1 patent drawingFigure 1A
  • EP2361314B1 patent drawingFigure 1B
  • EP2361314B1 patent drawing

AI summary

A region of the Chlamydia trachomatis pmpA gene has been identified which is useful for performing amplification assays to determine specifically whether C. trachomatis is present in the sample being tested. Oligonucleotides useful for performing thermal Strand Displacement Assay (tSDA) reactions on this gene are disclosed. The disclosed oligonucleotides can be used in an assay which is specific for multiple strains of C. trachomatis and which does not show cross reactivity with the genomes of other microorganisms or with human DNA.